English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In vivo, at low concentrations (less than or equal to 1 mug/ml), the antibiotic lipiarmycin specifically inhibits RNA synthesis in Bacillus subtilis. At a much higher concentration (100 mug/ml), syntheses of other macromolecules such as DNA and protein also appear to be suppressed. In vitro, the antibiotic caused 50% inhibition of DNA-dependent RNA-polymerase from B. subtilis at a concentration of 0.6 mug/ml and of that E. coli at 5 approximately 8 mug/ml. The activity of Escherichia coli DNA-polymerase I is inhibited 50% at 55 approximately 65 mug/ml. Lipiarmycin prevent ribonucleoside triphosphate polymerization only if added prior to the association between RNA-polymerase and DNA, and does not affect the elongation rate of RNA chains at concentrations up to 100 mug/ml. At that concentration, however, the antibiotic immediately blocks the polymerization of deoxyribonucleotide triphosphates catalyzed by DNA-polymerase I.

Lipiarmycin, a new antibiotic from Actinoplanes. III. Mechanism of action.